Drug Trial Radar · NCT00000796
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
525
Actual
Start
Not stated
Primary completion
Not stated
Study completion Oct 1998
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Not applicable
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
Conditions
- HIV Infections
- Tuberculosis
Interventions
CycloserineDrug
EthionamideDrug
Capreomycin sulfateDrug
Aminosalicylic acidDrug
Streptomycin sulfateDrug
Ethambutol hydrochlorideDrug
Amikacin sulfateDrug
IsoniazidDrug
PyrazinamideDrug
Pyridoxine hydrochlorideDrug
LevofloxacinDrug
RifampinDrug
ClofazimineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Cook County Hosp
Chicago, Illinois
Henry Ford Hosp
Detroit, Michigan
Interfaith Med Ctr
Brooklyn, New York
SUNY / Health Sciences Ctr at Brooklyn
Brooklyn, New York
Beth Israel Med Ctr
New York, New York
Clinical Directors Network of Region II
New York, New York
Bellevue Hosp / New York Univ Med Ctr
New York, New York
Saint Clare's Hosp and Health Ctr
New York, New York
Cornell Univ Med Ctr
New York, New York
Mount Sinai Med Ctr
New York, New York
Columbia Presbyterian Med Ctr
New York, New York
Harlem AIDS Treatment Group / Harlem Hosp Ctr
New York, New York
Bronx Lebanon Hosp Ctr
The Bronx, New York
Bronx Municipal Hosp Ctr/Jacobi Med Ctr
The Bronx, New York
Comprehensive Health Care Ctr / Bronx Municipal Hosp
The Bronx, New York
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp
The Bronx, New York
Montefiore Family Health Ctr / Bronx Municipal Hosp
The Bronx, New York
Samaritan Village Inc / Bronx Municipal Hosp
The Bronx, New York
Jack Weiler Hosp / Bronx Municipal Hosp
The Bronx, New York
Montefiore Med Ctr / Bronx Municipal Hosp
The Bronx, New York
North Central Bronx Hosp / Bronx Municipal Hosp
The Bronx, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.